COVID-19 Vaccination Safety in Patients who have had SARS-CoV-2-induced Chilblains
DOI:
https://doi.org/10.2340/actadv.v102.888Keywords:
chilblains, erythromelalgia, vaccine, vaccination, SARS-CoV-2, COVID-19, pernioAbstract
Abstract is missing (Short communication)
Downloads
References
Freeman E, McMahon D, Lipoff J, Rosenbach M, Kovarik C, Takeshita J, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol 2020; 83: 486-492.
https://doi.org/10.1016/j.jaad.2020.05.109 DOI: https://doi.org/10.1016/j.jaad.2020.05.109
Le Cleach L, Dousset L, Assier H, Fourati S, Barbarot S, Boulard C, et al. Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing. Br J Dermatol 2020; 183: 866-874.
https://doi.org/10.1111/bjd.19377 DOI: https://doi.org/10.1111/bjd.19377
Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, Moreno-Arrones OM, Saceda-Corralo D, Arana-Raja A, et al. Characterization of acute acral skin lesions in nonhospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol 2020; 83: e61-63.
https://doi.org/10.1016/j.jaad.2020.04.093 DOI: https://doi.org/10.1016/j.jaad.2020.04.093
Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183: 71-77.
https://doi.org/10.1111/bjd.19163 DOI: https://doi.org/10.1111/bjd.19163
Piccolo V, Bassi A, Russo T, Mazzatenta C, Baraldi M, Argenziano G, et al. Chilblain-like lesions and COVID-19: second wave, second outbreak. J Eur Acad Dermatol Venereol 2021; 35: e316-e318.
https://doi.org/10.1111/jdv.17145 DOI: https://doi.org/10.1111/jdv.17145
Hubiche T, Cardot-Leccia N, Le Duff F, Seitz-Polski B, Giordana P, Chiaverini C, et al. Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic. JAMA Dermatol 2021; 157: 202-206.
https://doi.org/10.1001/jamadermatol.2020.4324 DOI: https://doi.org/10.1001/jamadermatol.2020.4324
Poizeau F, Oger E, Barbarot S, Le Corre Y, Samimi M, Brenaut E, et al. Chilblains during lockdown are associated with household exposure to SARS-CoV-2. A multicentre case-control study. Clin Microbiol Infect 2022; 28: 285-291.
https://doi.org/10.1016/j.cmi.2021.09.032 DOI: https://doi.org/10.1016/j.cmi.2021.09.032
Ortega-Quijano D, Fernandez-Nieto D, Jimenez-Cauhe J, Cortes-Cuevas JL, Marcos-Mencia D, Rodriguez-Dominguez M, et al. Association between COVID-19 and chilblains: a case-control study. J Eur Acad Dermatol Venereol 2021; 35: e359-e361.
https://doi.org/10.1111/jdv.17195 DOI: https://doi.org/10.1111/jdv.17195
McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021; 85: 46-55.
https://doi.org/10.1016/j.jaad.2021.03.092 DOI: https://doi.org/10.1016/j.jaad.2021.03.092
Grieco T, Maddalena P, Sernicola A, Muharremi R, Basili S, Alvaro D, et al. Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study. Dermatol Ther 2021; 34: e15153.
https://doi.org/10.1111/dth.15153 DOI: https://doi.org/10.1111/dth.15153
Piccolo V, Bassi A, Argenziano G, Mazzatenta C, Cutrone M, Neri I, et al. BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2. J Eur Acad Dermatology Venereol 2021; 35: e493-e494.
https://doi.org/10.1111/jdv.17320 DOI: https://doi.org/10.1111/jdv.17320
Poizeau F, Barbarot S, Le Corre Y, Brenaut E, Samimi M, Aubert H, et al. The long-term outcome of patients with chilblains associated with SARS-CoV-2. Acta Derm Venereol 2021; 101: adv00614.
https://doi.org/10.2340/00015555-3930 DOI: https://doi.org/10.2340/00015555-3930
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383: 2603-2615.
https://doi.org/10.1056/NEJMoa2034577 DOI: https://doi.org/10.1056/NEJMoa2034577
McMahon DE, Kovarik CL, Damsky W, Rosenbach M, Lipoff JB, Tyagi A, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study. J Am Acad Dermatol 2022; 86: 113-121.
https://doi.org/10.1016/j.jaad.2021.09.002 DOI: https://doi.org/10.1016/j.jaad.2021.09.002
Moghadam P, Frumholtz L, Jaume L, De Masson A, Jachiet M, Begon E, et al. Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic. J Eur Acad Dermatol Venereol 2021; 35: e566-e568.
https://doi.org/10.1111/jdv.17393 DOI: https://doi.org/10.1111/jdv.17393
Published
How to Cite
License
Copyright (c) 2022 Florence Poizeau, Louise Triquet, Alain Dupuy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
